 | The 131st Annual Meeting (November 15-19, 2003) of APHA |
|
| The 131st Annual Meeting (November 15-19, 2003) of APHA |
Richard S Garfein, PhD, MPH, Division of HIV/AIDS Prevention, Epidemiology Branch, Centers for Disease Control and Prevention, 1600 Clifton Road, MS E-45, Atlanta, GA 30333, 404-639-6175, rlg6@cdc.gov
In June, 2002, community-based recruitment began in Baltimore, Chicago, Los Angeles, New York and Seattle for 15-30 year old injection drug users (IDUs) to participate in a randomized controlled trial of a 6-session small-group intervention designed to reduce their risk of HIV and HCV infection. The primary outcomes were to: 1) decrease the frequency and proportion of times participants inject with syringes that had been previously used by another IDU, 2) decrease the frequency and proportion of times participants have intercourse without a condom, and 3) to decrease the incidence of HCV infection. After completing an extensive baseline behavioral risk assessment on audio-assisted computerized self-interviewing (A-CASI) and serologic testing for HIV, HAV, HBV, and HCV, participants who where seronegative for HIV and HCV were invited to enroll in the intervention trial. All susceptible participants were offered free hepatitis A and B vaccinations. Participants enrolled in the trial will be reassessed for risk behaviors and viral infections at 3, 6 and 12 months post-intervention. To date, 1558 individuals have completed the baseline assessment. This session includes presentations based on data from these 1558 assessments.
Learning Objectives:
Presenting author's disclosure statement:
I have a significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.
Relationship: Federal government employee